CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Editas Medicine - EDIT CFD

    10.46
    3.42%
    0.07
    Low: 10.44
    High: 11.08
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Editas Medicine Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 10.83
    Open* 10.63
    1-Year Change* 7.37%
    Day's Range* 10.44 - 11.08
    52 wk Range 6.08-11.93
    Average Volume (10 days) 1.95M
    Average Volume (3 months) 34.68M
    Market Cap 826.54M
    P/E Ratio -100.00K
    Shares Outstanding 81.67M
    Revenue 24.61M
    EPS -2.71
    Dividend (Yield %) N/A
    Beta 1.93
    Next Earnings Date Feb 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 10.46 -0.19 -1.78% 10.65 11.17 10.37
    Dec 7, 2023 10.83 -0.15 -1.37% 10.98 11.17 10.73
    Dec 6, 2023 11.08 0.02 0.18% 11.06 11.66 10.82
    Dec 5, 2023 10.94 0.18 1.67% 10.76 11.13 10.51
    Dec 4, 2023 11.00 0.36 3.38% 10.64 11.22 10.51
    Dec 1, 2023 10.71 0.31 2.98% 10.40 10.81 10.26
    Nov 30, 2023 10.51 -0.22 -2.05% 10.73 10.95 10.40
    Nov 29, 2023 10.53 -0.14 -1.31% 10.67 11.19 10.53
    Nov 28, 2023 10.71 0.22 2.10% 10.49 10.76 10.32
    Nov 27, 2023 10.61 0.17 1.63% 10.44 10.77 10.17
    Nov 24, 2023 10.48 0.13 1.26% 10.35 10.86 10.35
    Nov 22, 2023 10.45 0.29 2.85% 10.16 10.69 10.10
    Nov 21, 2023 10.08 -0.47 -4.45% 10.55 10.61 10.05
    Nov 20, 2023 10.82 1.04 10.63% 9.78 11.11 9.77
    Nov 17, 2023 9.77 0.95 10.77% 8.82 9.79 8.81
    Nov 16, 2023 8.75 -0.03 -0.34% 8.78 8.89 8.49
    Nov 15, 2023 8.82 0.38 4.50% 8.44 9.12 8.44
    Nov 14, 2023 8.50 0.61 7.73% 7.89 8.53 7.89
    Nov 13, 2023 7.63 0.15 2.01% 7.48 7.63 7.12
    Nov 10, 2023 7.63 -0.18 -2.30% 7.81 7.85 7.42

    Editas Medicine Events

    Time (UTC) Country Event
    Tuesday, February 20, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Editas Medicine Inc Earnings Release
    Q4 2023 Editas Medicine Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 19.712 25.544 90.732 20.531 31.937
    Revenue 19.712 25.544 90.732 20.531 31.937
    Total Operating Expense 245.662 218.69 225.572 161.453 145.664
    Selling/General/Admin. Expenses, Total 70.704 76.183 67.576 64.555 55.01
    Research & Development 174.958 142.507 157.996 96.898 90.654
    Operating Income -225.95 -193.146 -134.84 -140.922 -113.727
    Interest Income (Expense), Net Non-Operating 4.225 2.342 2.605 7.313 3.445
    Other, Net 1.293 -1.698 16.259 -0.137 0.328
    Net Income Before Taxes -220.432 -192.502 -115.976 -133.746 -109.954
    Net Income After Taxes -220.432 -192.502 -115.976 -133.746 -109.954
    Net Income Before Extra. Items -220.432 -192.502 -115.976 -133.746 -109.954
    Net Income -220.432 -192.502 -115.976 -133.746 -109.954
    Total Adjustments to Net Income 0
    Income Available to Common Excl. Extra. Items -220.432 -192.502 -115.976 -133.746 -109.954
    Income Available to Common Incl. Extra. Items -220.432 -192.502 -115.976 -133.746 -109.954
    Diluted Net Income -220.432 -192.502 -115.976 -133.746 -109.954
    Diluted Weighted Average Shares 68.6648 67.6194 58.6094 49.9833 47.0977
    Diluted EPS Excluding Extraordinary Items -3.21026 -2.84685 -1.9788 -2.67581 -2.33459
    Diluted Normalized EPS -3.21026 -2.84685 -1.9788 -2.67581 -2.33459
    Total Extraordinary Items
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2.887 9.851 6.536 0.042 6.362
    Revenue 2.887 9.851 6.536 0.042 6.362
    Total Operating Expense 46.981 60.812 69.982 57.562 60.596
    Selling/General/Admin. Expenses, Total 17.202 23.008 17.984 16.236 16.937
    Research & Development 29.779 37.804 51.998 41.326 43.659
    Operating Income -44.094 -50.961 -63.446 -57.52 -54.234
    Interest Income (Expense), Net Non-Operating 3.811 3.509 1.419 1.793 0.546
    Other, Net -0.007 -1.584 1.289 0.001 0.235
    Net Income Before Taxes -40.29 -49.036 -60.738 -55.726 -53.453
    Net Income After Taxes -40.29 -49.036 -60.738 -55.726 -53.453
    Net Income Before Extra. Items -40.29 -49.036 -60.738 -55.726 -53.453
    Net Income -40.29 -49.036 -60.738 -55.726 -53.453
    Income Available to Common Excl. Extra. Items -40.29 -49.036 -60.738 -55.726 -53.453
    Income Available to Common Incl. Extra. Items -40.29 -49.036 -60.738 -55.726 -53.453
    Diluted Net Income -40.29 -49.036 -60.738 -55.726 -53.453
    Diluted Weighted Average Shares 71.3767 68.9242 68.7946 68.7361 68.6409
    Diluted EPS Excluding Extraordinary Items -0.56447 -0.71145 -0.88289 -0.81072 -0.77873
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.56447 -0.71145 -0.88289 -0.81072 -0.77873
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 356.754 507.31 419.087 463.844 374.776
    Cash and Short Term Investments 344.274 499.845 402.11 457.14 368.955
    Cash & Equivalents 141.522 203.519 139.682 238.183 134.776
    Total Receivables, Net 5.145 0.267 6.048 0.418 0.03
    Accounts Receivable - Trade, Net 5.145 0.267 6.048 0.418 0.03
    Prepaid Expenses 7.335 7.198 10.929 6.286 2.918
    Other Current Assets, Total 2.873
    Total Assets 514.321 677.483 572.602 508.885 420.386
    Property/Plant/Equipment, Total - Net 59.217 43.291 39.148 39.648 40.232
    Property/Plant/Equipment, Total - Gross 80.743 58.798 50.243 46.852 47.365
    Accumulated Depreciation, Total -21.526 -15.507 -11.095 -7.204 -7.133
    Other Long Term Assets, Total 5.253 6.811 4.703 5.393 5.378
    Total Current Liabilities 60.11 46.884 58.208 59.963 35.9
    Accounts Payable 9.511 5.05 6.408 5.843 5.327
    Accrued Expenses 42.378 30.501 30.857 27.924 12.813
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 8.221 11.333 20.943 26.196 17.76
    Total Liabilities 153.641 123.841 179.016 246.448 184.224
    Total Long Term Debt 0 0 0 0 32.417
    Capital Lease Obligations 0 32.417
    Other Liabilities, Total 93.531 76.957 120.808 186.485 115.907
    Total Equity 360.68 553.642 393.586 262.437 236.162
    Redeemable Preferred Stock 0 0
    Common Stock 0.007 0.007 0.006 0.005 0.005
    Additional Paid-In Capital 1442.41 1411.83 1058.82 811.546 652.464
    Retained Earnings (Accumulated Deficit) -1078.13 -857.699 -665.197 -549.221 -416.278
    Total Liabilities & Shareholders’ Equity 514.321 677.483 572.602 508.885 420.386
    Total Common Shares Outstanding 68.8474 68.4353 62.5635 54.5538 48.7589
    Short Term Investments 202.752 296.326 262.428 218.957 234.179
    Other Equity, Total -3.601 -0.493 -0.046 0.107 -0.029
    Long Term Investments 93.097 120.071 109.664
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 358.603 440.978 324.458 356.754 426.629
    Cash and Short Term Investments 349.617 431.968 318.439 344.274 419.617
    Cash & Equivalents 82.537 220.817 129.021 141.522 210.704
    Short Term Investments 267.08 211.151 189.418 202.752 208.913
    Total Receivables, Net 2.422 2.286 0.242 5.145 0.12
    Accounts Receivable - Trade, Net 2.422 2.286 0.242 5.145 0.12
    Prepaid Expenses 6.564 6.724 5.777 7.335 6.892
    Total Assets 504.65 541.953 464.105 514.321 531.029
    Property/Plant/Equipment, Total - Net 43.495 47.657 49.555 59.217 38.026
    Property/Plant/Equipment, Total - Gross 68.501 71.149 71.514 80.743 58.145
    Accumulated Depreciation, Total -25.006 -23.492 -21.959 -21.526 -20.119
    Long Term Investments 96.797 48.065 83.339 93.097 58.844
    Other Long Term Assets, Total 5.755 5.253 6.753 5.253 7.53
    Total Current Liabilities 58.603 54.513 57.155 60.11 42.289
    Accounts Payable 10.411 8.066 9.047 9.511 6.836
    Accrued Expenses 39.971 38.226 39.887 42.378 31.232
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 8.221 8.221 8.221 8.221 4.221
    Total Liabilities 144.188 142.036 146.632 153.641 116.284
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 85.585 87.523 89.477 93.531 73.995
    Total Equity 360.462 399.917 317.473 360.68 414.745
    Common Stock 0.008 0.008 0.007 0.007 0.007
    Additional Paid-In Capital 1574.38 1569.65 1446.91 1442.41 1436.42
    Retained Earnings (Accumulated Deficit) -1212.48 -1167.46 -1127.17 -1078.13 -1017.39
    Other Equity, Total -1.452 -2.285 -2.279 -3.601 -4.291
    Total Liabilities & Shareholders’ Equity 504.65 541.953 464.105 514.321 531.029
    Total Common Shares Outstanding 81.6688 81.6169 68.9936 68.8474 68.7617
    Redeemable Preferred Stock 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -220.432 -192.502 -115.976 -133.746 -109.954
    Cash From Operating Activities -177.349 -163.803 -179.843 -40.669 -45.707
    Cash From Operating Activities 6.337 5.053 3.959 2.83 3.254
    Non-Cash Items 28.57 45.056 34.394 24.315 34.105
    Cash Interest Paid
    Changes in Working Capital 8.176 -21.41 -102.22 65.932 26.888
    Cash From Investing Activities 114.068 -54.466 -140.522 12.252 -53.087
    Capital Expenditures -4.118 -7.977 -7.162 -6.167 -4.754
    Other Investing Cash Flow Items, Total 118.186 -46.489 -133.36 18.419 -48.333
    Cash From Financing Activities 1.284 282.106 224.122 131.824 86.94
    Financing Cash Flow Items
    Issuance (Retirement) of Stock, Net 1.284 282.106 224.122 131.824 87.797
    Issuance (Retirement) of Debt, Net 0 -0.857
    Net Change in Cash -61.997 63.837 -96.243 103.407 -11.854
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -49.036 -220.432 -159.694 -103.968 -50.515
    Cash From Operating Activities -35.768 -177.349 -135.076 -87.072 -49.227
    Cash From Operating Activities 1.544 6.337 4.76 3.156 1.558
    Non-Cash Items 5.397 28.57 23.704 18.106 11.665
    Changes in Working Capital 6.327 8.176 -3.846 -4.366 -11.935
    Cash From Investing Activities 23.267 114.068 141.596 52.369 56.371
    Capital Expenditures -1.84 -4.118 -3.494 -2.88 -2.248
    Other Investing Cash Flow Items, Total 25.107 118.186 145.09 55.249 58.619
    Cash From Financing Activities 0 1.284 0.665 0.585 0.218
    Issuance (Retirement) of Stock, Net 0 1.284 0.665 0.585 0.218
    Net Change in Cash -12.501 -61.997 7.185 -34.118 7.362
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.9883 8153727 962760 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 8.1361 6641679 -1522512 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 7.2207 5894436 224944 2023-06-30 LOW
    Deep Track Capital LP Hedge Fund 5.5044 4493416 1039672 2023-08-04 MED
    Avidity Partners Management LP Hedge Fund 3.675 3000000 3000000 2023-06-30 HIGH
    Marshall Wace LLP Investment Advisor/Hedge Fund 3.4769 2838317 2838317 2023-06-30 HIGH
    Woodline Partners LP Hedge Fund 3.3679 2749305 102685 2023-06-30 HIGH
    Two Sigma Investments, LP Hedge Fund 2.1766 1776820 155285 2023-06-30 HIGH
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.1649 1767229 155476 2023-06-30 LOW
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 1.9761 1613141 556168 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8287 1492823 41569 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 1.678 1369822 85885 2023-06-30 HIGH
    Morgan Stanley & Co. LLC Research Firm 1.4462 1180558 589720 2023-06-30 MED
    Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.2828 1047175 72126 2023-06-30 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.2539 1023589 -22023 2023-06-30 LOW
    Ghisallo Capital Management LLC Hedge Fund 1.1939 974618 974618 2023-06-30 HIGH
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.1354 926841 -143737 2023-06-30 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 0.9629 786069 287279 2023-06-30 MED
    Numeric Investors LLC Investment Advisor/Hedge Fund 0.9067 740174 191300 2023-06-30 MED
    Nuveen LLC Pension Fund 0.8399 685657 202691 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Editas Medicine Company profile

    Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
    Industry: Biotechnology & Medical Research (NEC)

    11 Hurley St
    CAMBRIDGE
    MASSACHUSETTS 02141-2110
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    71.33 Price
    -0.180% 1D Chg, %
    Long position overnight fee -0.0213%
    Short position overnight fee -0.0006%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    42,261.70 Price
    -3.660% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.63 Price
    -5.750% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,065.10 Price
    -0.100% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading